Esteban Jódar

10.9k total citations · 3 hit papers
85 papers, 3.0k citations indexed

About

Esteban Jódar is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Esteban Jódar has authored 85 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Endocrinology, Diabetes and Metabolism, 30 papers in Molecular Biology and 25 papers in Surgery. Recurrent topics in Esteban Jódar's work include Diabetes Treatment and Management (35 papers), Diabetes Management and Research (26 papers) and Metabolism, Diabetes, and Cancer (21 papers). Esteban Jódar is often cited by papers focused on Diabetes Treatment and Management (35 papers), Diabetes Management and Research (26 papers) and Metabolism, Diabetes, and Cancer (21 papers). Esteban Jódar collaborates with scholars based in Spain, United States and Denmark. Esteban Jódar's co-authors include Juan P. Frías, Manuel Muñoz‐Torres, Federico Hawkins, F. Escobar‐Jiménez, Ángel Rodríguez, Francesco Giorgino, Bernhard Ludvik, Katelyn Brown, Ross Bray and Laura Fernández Landó and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Esteban Jódar

79 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022 469 citations W. Timothy Garvey, Rachel L. Batterham et al. Nature Medicine profile →
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

2021 411 citations Bernhard Ludvik, Francesco Giorgino et al. profile →
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

2023 91 citations Stephen C. Bain, Esteban Jódar et al. profile →

Peers

Countries citing papers authored by Esteban Jódar

Since Specialization

Citations

This map shows the geographic impact of Esteban Jódar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esteban Jódar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esteban Jódar more than expected).

Fields of papers citing papers by Esteban Jódar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esteban Jódar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esteban Jódar. The network helps show where Esteban Jódar may publish in the future.

Co-authorship network of co-authors of Esteban Jódar

This figure shows the co-authorship network connecting the top 25 collaborators of Esteban Jódar. A scholar is included among the top collaborators of Esteban Jódar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esteban Jódar. Esteban Jódar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency 2025 ·Nutrients ·José-Luis Pérez-Castrillón, Esteban Jódar, Ján Nociar, (unknown), Dimitar B. Nikolov, (unknown), (unknown), Umberto Tarantino, Nadia Mehsen-Cêtre, (unknown), (unknown), Aintzane García‐Bea, Inmaculada Gilaberte	0
2	Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial 2025 ·Diabetologia ·Ildiko Lingvay, (unknown), Liming Chen, (unknown), Esteban Jódar, Tomoyuki Nishida, Jean‐Pierre Riveline, Daisuke Yabe, (unknown), Rosângela Réa	6
3	Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial 2024 ·Nutrients ·Esteban Jódar, José-Luis Pérez-Castrillón, Ján Nociar, (unknown), Dimitar B. Nikolov, (unknown), (unknown), Umberto Tarantino, Nadia Mehsen-Cêtre, (unknown), (unknown), Aintzane García‐Bea, Inmaculada Gilaberte	1
4	Actions to Improve the Secondary Prevention of Fragility Fractures in Women with Postmenopausal Osteoporosis: A Social Return on Investment (SROI) Study 2024 ·ClinicoEconomics and Outcomes Research ·(unknown), (unknown), Pilar Peris, (unknown), Íñigo Etxebarría-Foronda, (unknown), (unknown), Esteban Jódar, Antonio Naranjo, (unknown), Manuel García‐Goñi, Josep Vergés, (unknown), (unknown), (unknown), (unknown)	0
5	Efficacy and Safety of Calcifediol in Young Adults with Vitamin D Deficiency: A Phase I, Multicentre, Clinical Trial—POSCAL Study 2024 ·Nutrients ·(unknown), Mikel Urroz, (unknown), (unknown), Eric P. Zorrilla, (unknown), Esteban Jódar, (unknown), (unknown), Jesús Frías	2
6	Calcifediol: a review of its pharmacological characteristics and clinical use in correcting vitamin D deficiency 2023 ·European Journal of Nutrition ·Esteban Jódar, Claudia Campusano, Renate T. de Jongh, Michael F. Holick	27
7	Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial breakdown → 2022 ·Nature Medicine ·W. Timothy Garvey, Rachel L. Batterham, (unknown), Silvio Buscemi, (unknown), Juan P. Frías, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A. Wadden, Sean Wharton, (unknown)	469
8	EFFICACY AND SAFETY OF TIRZEPATIDE, A DUAL GIP/GLP-1 RECEPTOR AGONIST, COMPARED TO INSULIN DEGLUDEC IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3) 2022 ·Diabetologie und Stoffwechsel ·Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P. Frías, Laura Fernández Landó, Katelyn Brown, Ross Bray, Ángel Rodríguez, (unknown)	1
9	Wirkung von Semaglutid 2,4 mg vs. Placebo über 2 Jahre bei Erwachsenen mit Adipositas (STEP 5) (#7) 2022 ·Timothy Garvey, Rachel L. Batterham, (unknown), Silvio Buscemi, (unknown), (unknown), Juan P. Frías, Esteban Jódar, Kristian Kandler, Georgia Rigas, Thomas A. Wadden, Sean Wharton	0
10	Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials 2021 ·Diabetes Obesity and Metabolism ·Esteban Jódar, Irene Romera, Qianqian Wang, Sarah L. Roche, Luis‐Emilio García‐Pérez	3
11	Recomendaciones de la SEIOMM en la prevención y tratamiento del déficit de vitamina D 2021 ·SHILAP Revista de lepidopterología ·E. Casado, (unknown), (unknown), Pilar Peris, Esteban Jódar, Mercè Giner, José Luís Neyro, Javier del Pino, M. Sosa Henríquez, (unknown), (unknown)	7
12	Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial 2020 ·Journal of Bone and Mineral Research ·José Luis Pérez‐Castrillón, Antonio Dueñas‐Laita, Carlos Gómez‐Alonso, Esteban Jódar, Javier del Pino‐Montes, Maria Luisa Brandi, Fernando Cereto Castro, José Manuel Quesada‐Gómez, (unknown), José M. Olmos, (unknown), Bernat Galarraga, Jesús González-Macı́as, José Luís Neyro, Roger Bouillon, (unknown), (unknown), (unknown)	9
13	Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial 2020 ·Journal of Bone and Mineral Research ·José Luis Pérez‐Castrillón, Antonio Dueñas‐Laita, Maria Luisa Brandi, Esteban Jódar, Javier del Pino‐Montes, José Manuel Quesada‐Gómez, Fernando Cereto Castro, Carlos Gómez‐Alonso, (unknown), José M. Olmos, (unknown), Bernat Galarraga, Jesús González-Macı́as, Roger Bouillon, (unknown), (unknown), (unknown), (unknown)	40
14	<p>Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA</p> 2019 ·ClinicoEconomics and Outcomes Research ·(unknown), Michelle Mocarski, (unknown), Barnaby Hunt, (unknown), Esteban Jódar	3
15	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial 2019 ·Cardiovascular Diabetology ·Lawrence A. Leiter, Stephen C. Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, (unknown), Thomas K. Hansen, Ingrid Holst, Ildiko Lingvay	86
16	Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes ( AWARD ‐9) 2017 ·Diabetes Obesity and Metabolism ·Paolo Pozzilli, Paul Norwood, Esteban Jódar, Melanie J. Davies, T. Iványi, Honghua Jiang, (unknown), Zvonko Miličević	92
17	Características y tipos de agonistas del receptor de GLP-1. Una oportunidad más para la individualización terapéutica 2014 ·Medicina Clínica ·Esteban Jódar	2
18	Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study 2009 ·Aging Clinical and Experimental Research ·(unknown), M. Sosa Henríquez, Pedro Saavedra, Esteban Jódar, (unknown), J. M. Quesada, A. Torrijos, Ramón Pérez-Cano, Xavier Nogués, Díaz Curiel M, Marı́a Jesús Moro, Carlos García Gómez, (unknown), (unknown), José M. Olmos, Manuel Muñoz‐Torres, Núria Guañabens, Javier del Pino, Federico Hawkins	38
19	Long‐term follow‐up of bone mineral density in Addison's disease 2003 ·Clinical Endocrinology ·Esteban Jódar, (unknown), Guillermo Martínez, (unknown), Federico Hawkins	67
20	Bone mass in androgen-insensitivity syndrome: Response to hormonal replacement therapy 1995 ·Calcified Tissue International ·Manuel Muñoz‐Torres, Esteban Jódar, Miguel A. Quesada, F. Escobar‐Jiménez	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact